Hepatic sinusoidal obstructive syndrome (SOS), sometimes known as hepatic veno-occlusive disease (VOD), is a known complication and generally occurs as an acute process following hematopoietic stem cell transplant. SOS is occasionally difficult to diagnose and to differentiate from GvHD. Treatments of SOS are limited to supportive care and defibrotide, a recently FDA-approved medication indicated for SOS with multi-organ failure. 1 Although early recognition of SOS may improve outcomes, 2 optimal diagnostic and prognostic testing of SOS remains undefined. Here, we report two cases of SOS following haplo-identical stem cell transplantation and their clinical correlations with plasma biomarkers of SOS.
Both patients were enrolled on a clinical protocol approved by our institutional review board (14-H-0180, NCT02226861 and 94-H-0010, NCT00001397) after obtaining informed consent, including the use of samples for research (04-H-0012, NCT00071045) in accordance with the Declaration of Helsinki. Patients received myeloablative conditioning regimens of fludarabine 120 mg/m 2 and TBI 1200 cGy. Thereafter the patients received donor lymphocyte infusion (2 × 10 8 CD3+ cells per kg) on day − 6, followed by post-donor lymphocyte infusion cyclophosphamide 120 mg/kg over days − 3 and − 2. CD34+ selected, peripheral blood progenitor cells were infused on day 0. Sirolimus was initiated on day − 1 and ultra-low-dose interleukin 2 (aldesleukin, 100 000 IU/m 2 ) was given SC daily starting day +1 as GvHD prophylaxis. 3 Serial plasma samples were collected post transplant and levels of biomarkers (suppression of tumorigenicity-2(ST2), Reg3α, sTNFR1, angiopoietin-2 (ANG2)) were measured using a multiplex microfluidic channel assay (ProteinSimple, San Jose, CA, USA). 4 Case 1 is a 39-year-old woman with relapsed AML in third CR (CR3) who underwent haplo-identical stem cell transplantation using her brother as a donor. On day +4 after transplant she developed cytokine release syndrome thought to be associated with her haploidentical transplant. This manifested as pericardiac and pleural effusions and was treated successfully with tocilizumab. She concomitantly developed Stenotrophomonas bacteremia and fungemia with Candida krusei and was treated appropriately with improvement in her symptoms. On day +13 after transplant, she developed engraftment syndrome with fever, pulmonary infiltration and persistent pleural effusions requiring systemic steroids. Despite improvement of the engraftment syndrome with steroids, she developed an acute rise in bilirubin, new-onset ascites, hepatomegaly and acute renal failure, consistent with a clinical diagnosis of severe SOS with multi-organ failure on day +22, and was started on defibrotide ( Figure 1 ). Even with maximal medical support, she developed progressive hepatic encephalopathy and exacerbation of renal failure and expired on day +32.
Case 2 is a 35-year-old male with relapsed Hodgkin's lymphoma in CR4 who underwent haplo-identical stem cell transplantation using his mother as the donor. On day +19, he developed skin and upper gut GvHD initially responsive to steroids, however, after discontinuation of ultra-low-dose interleukin 2, GvHD recurred as steroid-refractory lower gut and liver GvHD on day +96. He was started on infliximab and basiliximab with improvement in his gastrointestinal symptoms. Around this time, his liver function T-bil Figure 1 . Timeline of treatments and total bilirubin and corresponding plasma levels of biomarkers.
tests began to rise accompanied by ascites and lower-extremity edema (Figure 2a). A liver biopsy (Figures 2b and c) obtained on day +127 demonstrated sinusoidal dilatation and hepatic venules
showing new collagen deposition consistent with SOS plus underlying features of liver GvHD. Prompted by the confirmatory liver biopsy, we initiated defibrotide. The condition responded sluggishly with a significant reduction in his bilirubin over the course of 56 days of therapy. We studied both patients to correlate the clinical picture with candidate biomarkers using a rapid and reproducible system for measurement. 4 Akil et al. 5 reported that both ANG2 and ST2 are potential biomarkers for the diagnosis of SOS. We aimed to annotate the clinical events to the levels of serial biomarker measurements. In the first case, the significant ST2 elevation and subsequent decline was correlated to engraftment syndrome, while sustained elevation of ANG2 was observed despite treatment with high-dose steroids and clinical improvement of engraftment syndrome. The persistent elevation of ANG2 levels correlated to the levels of total bilirubin and emergence of the full clinical syndrome of SOS. Despite our best efforts, our first patient unfortunately expired, likely due to the severe multi-organ failure associated not only with SOS but also with her other comorbidities at the time. In the second case, the rise in ST2 correlated to GvHD of the GI tract and liver, while ANG2 became elevated at the onset of SOS. A further complicating feature of the second case is the late onset of SOS. Generally, SOS occurs within the first 21 days of hematopoietic stem cell transplant. There have been few cases of late diagnoses of SOS and the frequency of this disease may be underrepresented due to other complications such as hepatitis, sepsis or GvHD. 6, 7 Nevertheless, this is the first case where we were able to show that, in late-onset SOS, ANG2 correlates with the diagnosis of SOS and improves with defibrotide.
ST2 has been well characterized as a biomarker associated with severe engraftment syndrome 8 and high-risk GvHD. 9 ANG2 is secreted from endothelial growth factors and inhibits proangiogenic angiopoietin 1, modulating vascular permeability and leakage. 10 While our observations were limited to two patients, it is reasonable to hypothesize that ANG2 would rise with the increasing endothelial damage induced by SOS. Furthermore, the trend of ANG2 in correlation to ST2 may be useful to distinguish from GvHD in atypical cases of SOS. Elevated levels of L-Ficolin, vascular cell adhesion molecule-1 and hyaluronic acid also correlate with a diagnosis of SOS. 5 Lack of these biomarker measurements is a limitation of our study since our current assay panel is restricted to ST2, Reg3α, sTNFR1 and ANG2. In future studies, we plan to expand the biomarker assay panel incorporating additional biomarkers so that we can perform a comprehensive monitoring of post-transplant complications.
Serial biomarker profiling is a promising method to distinguish the relative contributions of inter-related complications (engraftment syndrome, GvHD, SOS) and may provide prognostic information. With further confirmation, we may expect that serial biomarker measurements will become routine and extended to real-time monitoring for future transplant patients. Letter to the Editor
